Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CMV-specific T cell therapy.

Hermann Einsele1, Markus Kapp, Götz Ulrich Grigoleit

  • 1Medizinische Klinik und Poliklinik II, Julius Maximilians University of Würzburg, Germany.

Blood Cells, Molecules & Diseases
|September 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors.

Cancer communications (London, England)·2025
Same author

Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Blood advances·2024
Same author

Impaired T cells and "memory-like" NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation.

Blood advances·2024
Same author

Identification of novel canonical and cryptic HCMV-specific T-cell epitopes for HLA-A∗03 and HLA-B∗15 via peptide-PRISM.

Blood advances·2023
Same author

C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety Profile.

Clinical nuclear medicine·2023
Same author

CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis.

Frontiers in immunology·2023

Human cytomegalovirus (CMV) infection is a major risk after stem cell transplants (SCT). Restoring CMV-specific T cell immunity is key to preventing CMV disease. This review covers therapeutic T cell strategies for CMV infection post-SCT.

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Virology

Background:

  • Human cytomegalovirus (CMV) infection is a life-threatening complication following allogeneic stem cell transplantation (SCT).
  • Reconstitution of CMV-specific T cell responses post-SCT is crucial for protection against CMV disease.
  • Effective strategies are needed to enhance T cell immunity against CMV in bone marrow transplant recipients.

Purpose of the Study:

  • To review the therapeutic applications of CMV-specific T cells in combating CMV infection.
  • To explore different strategies for improving T cell immunity against CMV in SCT patients.
  • To discuss methods for generating and administering CMV-specific T cells for therapeutic benefit.

Main Methods:

  • Review of existing literature on CMV-specific T cell therapies post-SCT.

Related Experiment Videos

  • Analysis of strategies involving direct transfer of donor-derived CMV-specific T cells.
  • Examination of methods for in vitro activation and expansion of CMV-specific T cells using antigen-presenting cells (APCs).

    • Main Results:

    • CMV-specific T cells, either directly transferred or expanded in vitro, show therapeutic potential.
    • Different approaches exist for generating CMV-specific T cell therapies.
    • The reconstitution of T cell immunity is a critical factor in managing CMV post-transplant.

    Conclusions:

    • Therapeutic application of CMV-specific T cells offers a promising strategy to control CMV infection after SCT.
    • Both direct T cell transfer and ex vivo expanded T cells are viable approaches.
    • Further research and clinical application of these T cell-based therapies are warranted to improve patient outcomes.